New Alzheimer's Drug Donanumab: Approval, Trials, and Challenges

from Morning Medical with Dr. Chow · host Chi-Ming Chow

Dr. Chi-Ming Chow discusses the FDA approval of the new Alzheimer's drug Donanumab, comparing it to Lekembi and addressing its clinical trial results, side effects, and logistical challenges. He also covers the WHO's new clinical treatment guideline for smoking cessation, recommended treatments, and vaping products, along with global and Canadian tobacco use statistics.

Episode metadata supplied by the publisher feed · Published Jul 3, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

New Alzheimer's Drug Donanumab: Approval, Trials, and Challenges

0:00 20:29

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Morning Medical with Dr. Chow?

This episode is 20 minutes long.

When was this Morning Medical with Dr. Chow episode published?

This episode was published on July 3, 2024.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Morning Medical with Dr. Chow episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!